PMID- 15274358
OWN - NLM
STAT- MEDLINE
DCOM- 20040910
LR  - 20091119
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 24
IP  - 3a
DP  - 2004 May-Jun
TI  - Expression of bFGF, VEGF and c-met and their correlation with microvessel density 
      and progression in prostate carcinoma.
PG  - 1797-804
AB  - BACKGROUND: Previously, we found angiogenesis measured as microvessel density 
      (MVD) to be associated with both pathological stage and clinical outcome after 
      radical prostatectomy (RP). In addition, we have shown that Vascular Endothelial 
      Growth Factor (VEGF) is one of the important inducers of angiogenesis in prostate 
      cancer (PC). The aim of this study was to investigate the expression of 
      additional angiogenic factors, namely basic Fibroblast Growth Factor (hFGF) and 
      the c-met receptor of Hepatocyte Growth Factor/Scatter Factor (HGF/SF) in PC. 
      MATERIALS AND METHODS: Ninety-eight paraffin-embedded RP specimens and 20 
      adjacent normal prostatic tissues were evaluated for factor VIII staining and 
      microvessel counting. Expression of VEGF (n=55), bFGF (n=65) and c-met (n=66) was 
      studied by immunohistochemistry. Results were correlated with pathological grade 
      and stage, MVD and clinical outcome. RESULTS: While adjacent benign tissue in RP 
      specimens generally showed low MVD, VEGF-, bFGF- and c-met-expression, this was 
      different in PC. All angiogenesis inducers were associated with stage while c-met 
      as well as VEGF expression were associated with grade. Tumor progression was 
      associated with grade and MVD. There was a clear correlation between VEGF and 
      c-met expression and MVD. CONCLUSION: VEGF and c-met expression increase with 
      tumor stage and grade, while bFGF expression increases only with tumor stage. In 
      addition to VEGF, c-met seems to be important and clinically relevant to the 
      induction of angiogenesis in PC. Both VEGF and c-met appear to influence tumor 
      progression, mainly through their effect on MVD.
FAU - Strohmeyer, Dagmar
AU  - Strohmeyer D
AD  - Department of Urology, University of Innsbruck, Austria. 
      strohmeyer-kiefersfelden@t-online.de
FAU - Strauss, Franz
AU  - Strauss F
FAU - Rossing, Christian
AU  - Rossing C
FAU - Roberts, Chris
AU  - Roberts C
FAU - Kaufmann, Olaf
AU  - Kaufmann O
FAU - Bartsch, Georg
AU  - Bartsch G
FAU - Effert, Peter
AU  - Effert P
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 9001-27-8 (Factor VIII)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
SB  - IM
MH  - Factor VIII/metabolism
MH  - Fibroblast Growth Factor 2/*biosynthesis
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Neoplasm Staging
MH  - Neovascularization, Pathologic/*metabolism
MH  - Paraffin Embedding
MH  - Prostatic Neoplasms/*blood supply/metabolism/pathology
MH  - Proto-Oncogene Proteins c-met/*biosynthesis
MH  - Vascular Endothelial Growth Factor A/*biosynthesis
EDAT- 2004/07/28 05:00
MHDA- 2004/09/11 05:00
CRDT- 2004/07/28 05:00
PHST- 2004/07/28 05:00 [pubmed]
PHST- 2004/09/11 05:00 [medline]
PHST- 2004/07/28 05:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 2004 May-Jun;24(3a):1797-804.